COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY
The present invention provides novel compounds of Formulas (I) and (II) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for trea...
Saved in:
Main Authors | , , , , , , , , , , |
---|---|
Format | Patent |
Language | English French |
Published |
08.12.2016
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | The present invention provides novel compounds of Formulas (I) and (II) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases, e.g., cancers (e.g., breast cancer, prostate cancer, lymphoma, lung cancer, pancreatic cancer, ovarian cancer, neuroblastoma, or colorectal cancer), benign neoplasms, angio genesis, inflammatory diseases, fibrosis (e.g., polycystic kidney disease), autoinflammatory diseases, and autoimmune diseases in a subject.
La présente invention concerne de nouveaux composés de formule (I) et de formule (II), et leurs sels, solvates, hydrates, tautomères, stéréo-isomères, dérivés marqués de manière isotopique, pharmaceutiquement acceptables, et des compositions de ceux-ci. L'invention concerne également des procédés et des kits impliquant ces composés ou compositions pour le traitement ou la prévention de maladies prolifératives, notamment les cancers (par exemple, cancer du sein, cancer de la prostate, lymphome, cancer du poumon, cancer du pancréas, cancer de l'ovaire, neuroblastome ou cancer colorectal), les néoplasmes bénins, l'angiogenèse, des maladies inflammatoires, la fibrose (par exemple, la maladie polykystique des reins), des maladies auto-inflammatoires et des maladies auto-immunes chez un sujet. |
---|---|
Bibliography: | Application Number: WO2016US35690 |